Information Journal Paper
APA:
Copy. (2018). Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 142(5), 1665-1699. SID. https://sid.ir/paper/770423/en
Vancouver:
Copy. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY[Internet]. 2018;142(5):1665-1699. Available from: https://sid.ir/paper/770423/en
IEEE:
Copy, “Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations,” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 142, no. 5, pp. 1665–1699, 2018, [Online]. Available: https://sid.ir/paper/770423/en